This treatment strategy can further mitigate endothelial dysfunction associated with type 2 diabetes [28,33] and we speculate that it occurs via a pharmacological “priming” or sensitization of endothelial KCa channel activity and EDH-type signaling [53]. Here, CSN3 is linked to type 2 diabetes mellitus.